CSF SNAP-25 in schizophrenia and bipolar illness: A pilot study

Peter M. Thompson, Cynthia Rosenberger, Clifford Qualls

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Research efforts to identify and understand the pathophysiology of schizophrenia and bipolar illness are limited by the inability to study neuronal tissue of living patients. An alternative to sampling brain tissue from living patients is to measure neuronal proteins found in cerebral spinal fluid. One such candidate protein is synaptosomal-associated protein 25kDa. Our hypothesis is that the level of this protein in cerebral spinal fluid may be a marker of neuronal pathology. Cerebral spinal fluid from headache, schizophrenic, bipolar, and control subjects was used to measure the SNAP-25 level by quantitative dot blotting. Schizophrenic subjects had significantly elevated levels of SNAP-25 as compared to headache and control subjects. However, there was no significant difference between the bipolar group and schizophrenic or control groups. This study reports on a potentially useful clinical marker in schizophrenia, and the presence of elevated cerebral spinal fluid SNAP-25 may indicate alterations in neuronal functioning.

Original languageEnglish (US)
Pages (from-to)717-722
Number of pages6
Issue number6
StatePublished - Dec 1999


  • Bipolar illness
  • Cerebral spinal fluid
  • SNAP-25
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health


Dive into the research topics of 'CSF SNAP-25 in schizophrenia and bipolar illness: A pilot study'. Together they form a unique fingerprint.

Cite this